Multi-omics "upstream analysis" of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer
2016-12 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Kel AE, Stegmaier P, Valeev T, Koschmann J, Poroikov V, Kel-Margoulis OV, et al. Multi-omics "upstream analysis" of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer. EuPA open proteomics. 2016;13:1-13. doi:10.1016/j.euprot.2016.09.002.
Documents & Media
Details
- Authors
- Kel, Alexander E.; Stegmaier, Philip; Valeev, Tagir; Koschmann, Jeannette; Poroikov, Vladimir; Kel-Margoulis, Olga V.; Wingender, Edgar
- Abstract
- We present an "upstream analysis" strategy for causal analysis of multiple "-omics" data. It analyzes promoters using the TRANSFAC database, combines it with an analysis of the upstream signal transduction pathways and identifies master regulators as potential drug targets for a pathological process. We applied this approach to a complex multi-omics data set that contains transcriptomics, proteomics and epigenomics data. We identified the following potential drug targets against induced resistance of cancer cells towards chemotherapy by methotrexate (MTX): TGFalpha, IGFBP7, alpha9-integrin, and the following chemical compounds: zardaverine and divalproex as well as human metabolites such as nicotinamide N-oxide.
- Issue Date
- December-2016
- Journal
- EuPA open proteomics
- ISSN
- 2212-9685
- eISSN
- 2212-9685
- Language
- English
